Laboratório de Pesquisas Clínica e Experimental em Biologia Vascular, Departamento de Clínica Médica, Centro Biomédico, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Clinics (Sao Paulo). 2009 May;64(5):415-20. doi: 10.1590/s1807-59322009000500008.
To study if metformin, when administered to first-degree relatives of type 2 diabetes mellitus subjects who have metabolic syndrome and normal glucose tolerance, could improve the cardiovascular risk profile and reduce the levels of both C-reactive protein and fibrinogen.
Metabolic syndrome is associated with higher cardiovascular morbidity and mortality. Metformin has vasculo-protective effects even in normoglycemic subjects, and C-reactive protein and fibrinogen are considered markers of endothelial injury and inflammation.
Thirty-one non-diabetic first-degree relatives of type 2 diabetes mellitus subjects with metabolic syndrome were randomized (1:1) and double-blinded for placement in the placebo and metformin groups (850 mg bid/+/-90 days); 16 subjects were administered metformin (mean age 40.0 [33.5-50] years; 13 females) and 15 subjects were in the placebo group (mean age 37.0 [32-42] years; 9 females). Blood samples were collected at baseline and at the end of treatment for biochemical analyses, including an assessment of C-reactive protein and fibrinogen levels.
Metformin improved the lipid profile and decreased fasting plasma glucose, systolic blood pressure, weight and body mass index without changing body composition. For those in the placebo we identified no changes in fibrinogen (282.2 [220.4-323.7] mg/L vs. 286.7 [249.6-295.1] mg/L; NS) or in C-reactive protein levels (0.68 [0.3-1.2] vs. 0.64 [0.3-1.0] mg/L; NS). The same was also observed for the levels of fibrinogen (303.9 [217.6-347.6] mg/L vs. 290.9 [251.5-301.9] mg/L; NS) and C-reactive proteins (0.78 [0.3-1.1] vs. 0.80 [0.4-0.9] mg/L; NS) in the metformin group.
Metformin treatment in first-degree relatives of type 2 diabetes mellitus sufferers who have metabolic syndrome and normal glucose tolerance improved the cardiovascular risk profile without changing the levels of C-reactive protein and fibrinogen.
研究二甲双胍在代谢综合征但血糖正常的 2 型糖尿病患者一级亲属中应用是否能改善心血管风险特征，并降低 C 反应蛋白和纤维蛋白原的水平。
代谢综合征与更高的心血管发病率和死亡率相关。二甲双胍具有血管保护作用，甚至在血糖正常的患者中也是如此，C 反应蛋白和纤维蛋白原被认为是内皮损伤和炎症的标志物。
31 名非糖尿病的 2 型糖尿病患者一级亲属被随机分为安慰剂组和二甲双胍组（1：1），并进行双盲治疗（二甲双胍 850mg bid/+/90 天）；16 名患者服用二甲双胍（平均年龄 40.0[33.5-50]岁；13 名女性），15 名患者服用安慰剂（平均年龄 37.0[32-42]岁；9 名女性）。在基线和治疗结束时采集血样进行生化分析，包括 C 反应蛋白和纤维蛋白原水平的评估。
二甲双胍改善了血脂谱，降低了空腹血糖、收缩压、体重和体重指数，而不改变身体成分。在安慰剂组中，我们没有发现纤维蛋白原（282.2[220.4-323.7]mg/L 比 286.7[249.6-295.1]mg/L；NS）或 C 反应蛋白水平（0.68[0.3-1.2]比 0.64[0.3-1.0]mg/L；NS）的变化。同样，在二甲双胍组中，纤维蛋白原（303.9[217.6-347.6]mg/L 比 290.9[251.5-301.9]mg/L；NS）和 C 反应蛋白（0.78[0.3-1.1]比 0.80[0.4-0.9]mg/L；NS）的水平也没有变化。
二甲双胍治疗代谢综合征但血糖正常的 2 型糖尿病患者一级亲属，改善了心血管风险特征，而不改变 C 反应蛋白和纤维蛋白原的水平。
